Candel Therapeutics, Inc.

NASDAQ:CADL

Biotechnology

Healthcare
$5.32 +0.56%

+$0.05 today

Market cap
$417.33M
Beta
-0.48
P/E (TTM)
-9.2
EPS (TTM)
-$0.87
52W Low $4.35High $9.57

Volume 1.39M

Average 1.82M

CADL Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Candel Therapeutics, Inc.NASDAQ: CADL

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 62.36M shares rose 96.9% year over year, ahead of the +73.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 13.6% from the prior quarter. Over 3 fiscal years it compounded at +22.5% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +96.9% holds above the trailing-twelve-month pace of +73.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
62.36M+13.6% QoQ
Last fiscal yearDec 2025
52.96M+67.2% YoY
LTMMar 2026
55.91M+73.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+96.9%——
1 year+67.2%——
3-year CAGR+22.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
52.96M USD
Year-over-year change
+67.2%
4-year CAGR
+16.6%

Weighted Avg Shares (Diluted) vs competitors

How CADL compares with its peers on the latest reported figures

  • CADL's LTM Mar 2026 weighted avg shares (diluted) of 55.91M shares is the 7th highest of the 10 companies compared; the peer median is 72.17M shares.
  • Its year-over-year change of +73.2% is the highest of 10, against a peer median of +4.3%.
  • Over three fiscal years its annual growth of +22.5% compares with a peer median of +14.4%.
CADL Competitors Peer median
Weighted Avg Shares (Diluted) for CADL and competitors
Company Period LTM YoY 3-year CAGR
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026432.9M +30.6%+30.9%
ORICORIC Pharmaceuticals, Inc.LTM Mar 202692.59M +31.1%+30.3%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 202686.55M +1.2%+12.5%
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
NBPNovaBridge BiosciencesLTM Sep 202572.17M -11.6%-20.4%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
CADLCandel Therapeutics, Inc.LTM Mar 202655.91M +73.2%+22.5%
PBYIPuma Biotechnology, Inc.LTM Mar 202650.86M +3.4%+4.1%
GNLXGenelux CorporationLTM Mar 202636.38M +11.4%+14.8%
IMMXImmix Biopharma, Inc.LTM Mar 202634.62M +19.9%+33.4%
Peer median (excluding CADL) 72.17M+4.3%+14.4%

Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue125K125K000
Cost of Revenue00000
Gross Profit125K125K000
Gross Margin100.0%100.0%———
Research & Development15.18M20.79M24.51M19.31M30.5M
Selling, General & Admin10.67M14.06M13.89M14.06M17.77M
Operating Expenses24.78M34.8M38.39M33.37M48.27M
Depreciation & Amortization232K778K960K990K845K
EBITDA(24.42M)(16.31M)(34.38M)(52.1M)(35.22M)
EBITDA Margin-19534.4%-13046.4%———
Operating Income(24.65M)(34.67M)(38.39M)(33.37M)(48.27M)
Operating Margin-19720.0%-27739.2%———
Interest Income01.22M2.08M1.09M3.92M
Interest Expense53K1.71M2.6M2.09M2.12M
Other Income / Expenses(10.4M)15.93M452K(21.81M)10.08M
Income Before Tax(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Pre-Tax Margin-28899.2%-15035.2%———
Income Tax Expense00000
Net Income(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Net Margin-28899.2%-15035.2%———
EPS (Basic)(1.26)(0.10)(1.31)(1.74)(0.72)
EPS (Diluted)(1.26)(0.10)(1.31)(1.74)(0.72)
Weighted Avg Shares28.69M28.82M28.94M31.68M52.96M
Weighted Avg Shares (Diluted)28.69M28.82M28.94M31.68M52.96M

Candel Therapeutics, Inc.

NASDAQ:CADL

Intrinsic Alpha fair value

Locked

Current Price

$5.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.